Positive Glufosfamide Results From A Phase 2 Clinical Trial Presented At European Cancer Conference (ECCO)

September 27th, 2007 | Category: Cancer

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), announced that results from a Phase 2 trial of glufosfamide plus gemcitabine were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain. In the Phase 2 clinical trial of glufosfamide in combination with gemcitabine

for the treatment of advanced pancreatic cancer, six-month and one-year survival were 50% (95% CI: 31-67%) and 32% (95% CI: 16 - 49%), respectively. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Glufosfamide Results From Phase 3 Clinical Trial Presented At European Cancer Conference (ECCO)
  • Positive Interim Results Of Phase Ia/Ib Trials To Be Presented At UK Conference
  • Genasense(R) Clinical details In Patients With Advanced Melanoma And Chronic Lymphocytic Leukemia To Be Presented At ECCO Meeting In Barcelona
  • Array BioPharma Presents Additional Positive Phase 1 Results In Two Programs At The 2008 Annual European Congress Of Rheumatology
  • NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti Tumor Activity And Improved Pharmacokinetic Profile In Preclinical Studies Presented At ECCO

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.